Aaron Holley, MD
Pulmonary Disease · Bethesda, MDNPI 1750485439
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (60.0%), grants and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by GSK at 60.0% of the total. Reporting peaked in 2020 at $2,000 and has fallen 90.4% since, to $191 in 2025.
Across 27 payments — averaging $123.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Genentech, Inc.$1K
- Shionogi Inc$168
- AstraZeneca$76
- Mallinckrodt Hospital Products Inc.$28
- Inspire Medical Systems, Inc.$25
- plus $37 from 2 others
Across 19 payments — averaging $3660.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$44K
- GSK$26K
What the payments were for
- Consulting fees$2,00060%
- Grants$1,00030%
- Food & beverage$1665%
- Education$1685%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $2,000 |
| Genentech, Inc. | 1 | $1,000 |
| Shionogi Inc | 16 | $168 |
| AstraZeneca | 4 | $76 |
| Mallinckrodt Hospital Products Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Merck | 1 | $24 |
| AbbVie | 1 | $13 |
How this compares
$3,334 in reported general payments places this provider in the 65th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 12 | $44,496 |
| Spiriva RespimatTiotropium Bromide | 21 | $18,348 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $15,776 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,281 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,877 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,504 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,135 |
| Fluticasone Propionate | 19 | $461 |
| Zolpidem Tartrate | 18 | $271 |
| Prednisone | 31 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta | $2,000 | $60,27228 claims |
| AstraZenecaSymbicort | $76 | $7,28119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Bethesda
- da Wei LiaoBethesda$310K
- Kenneth OlivierBethesda$37K
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.